MedTrace Logo

A Study of Pemafibrate in Patients With Nonalcoholic Fatty Liver Disease (NAFLD)

NCT03350165 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 118

Last updated 2021-04-09

No results posted yet for this study

Summary

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Pemafibrate in Patients With Nonalcoholic Fatty Liver Disease.

Conditions

  • Non-Alcoholic Fatty Liver Disease

Interventions

DRUG

K-877

0.2mg tablet

DRUG

Placebo

K-877 matching placebo tablet

Sponsors & Collaborators

  • Kowa Company, Ltd.

    lead INDUSTRY

Principal Investigators

  • Ryohei Tanigawa · Clinical Development Dept. Ⅰ

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-12-27
Primary Completion
2019-04-03
Completion
2020-06-30

Countries

  • Japan

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03350165 on ClinicalTrials.gov